Individualized Adaptive De-escalated Radiotherapy for HPV-related Oropharynx Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

91

Participants

Timeline

Start Date

May 21, 2018

Primary Completion Date

May 5, 2023

Study Completion Date

May 5, 2025

Conditions
Oropharynx Cancer
Interventions
DRUG

Carboplatin

AUC=1 weekly during radiation therapy. Carboplatin will be given once a week in combination with paclitaxel (standard treatment), concurrent with radiation therapy. Given IV.

RADIATION

Radiation Therapy

Patients will initially receive a single prescription of 70 Gy to PTV1 in 35 fractions with RT given once daily, 5 days a week along with weekly carboplatin and paclitaxel (standard therapy). Dose will be reduced to 54Gy to high risk PTV and 43.2Gy to low risk PTV all in 27 fractions for patients who meet pPET-CT and iPET-CT parameters.

DRUG

Paclitaxel

30 mg/m2 weekly during radiation therapy. Paclitaxel will be given once a week in combination with carboplatin (standard treatment), concurrent with radiation therapy. Given IV.

Trial Locations (2)

48109

University of Michigan Hospital, Ann Arbor

VA Ann Arbor Healthcare System, Ann Arbor

All Listed Sponsors
collaborator

VA Ann Arbor Healthcare System

FED

collaborator

National Cancer Institute (NCI)

NIH

lead

University of Michigan Rogel Cancer Center

OTHER

NCT03416153 - Individualized Adaptive De-escalated Radiotherapy for HPV-related Oropharynx Cancer | Biotech Hunter | Biotech Hunter